Sydney Australia, 26 February 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 for Recce’s Anti-infectives, expiry 2041. The Japan Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably: - Process for preparation of RECCE® anti-infectives - Use of R327/R529 for the treatment of ...
[ more ]
